A phase II study of allogeneic hematopoetic stem cell transplant for B-cell non-Hodgkin lymphoma using Zevalin, fludarabine and melphalan

Trial Profile

A phase II study of allogeneic hematopoetic stem cell transplant for B-cell non-Hodgkin lymphoma using Zevalin, fludarabine and melphalan

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Fludarabine (Primary) ; Ibritumomab tiuxetan (Primary) ; Melphalan (Primary) ; Rituximab; Sirolimus; Tacrolimus; Tacrolimus
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Graft-versus-host disease; MALT lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 May 2016 Planned primary completion date changed from 1 Jan 2017 to 1 April 2017.
    • 01 Jun 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 10 Mar 2011 Planned end date changed from 1 Jan 2011 to 1 Jun 2020 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top